Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

Fig. 1

ONC201 acts in combination with bevacizumab to significantly impact colorectal cancer growth in vivo. a Final tumor measurements of HT29 human cell colorectal tumors in combination with ONC201 and bevacizumab at the indicated doses after 4 weeks. b Representative fluorescent images. c Final tumor measurements of CRC PDX tumors in SCID mice after 5 weeks. d Representative image of PDX tumors. Bevacizumab is 5 mg/kg every 2 weeks. N = 5

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us